Virology, epidemiology, pathogenesis, and control of enterovirus 71

Tom Solomon, Penny Lewthwaite, David Perera, Mary Jane Cardosa, Peter McMinn, Mong How Ooi

First isolated in California, USA, in 1969, enterovirus 71 (EV71) is a major public health issue across the Asia-Pacific region and beyond. The virus, which is closely related to polioviruses, mostly affects children and causes hand, foot, and mouth disease with neurological and systemic complications. Specific receptors for this virus are found on white blood cells, cells in the respiratory and gastrointestinal tract, and dendritic cells. Being an RNA virus, EV71 lacks a proofreading mechanism and is evolving rapidly, with new outbreaks occurring across Asia in regular cycles, and virus gene subgroups seem to differ in clinical epidemiological properties. The pathogenesis of the severe cardiopulmonary manifestations and the relative contributions of neurogenic pulmonary oedema, cardiac dysfunction, increased vascular permeability, and cytokine storm are controversial. Public health interventions to control outbreaks involve social distancing measures, but their effectiveness has not been fully assessed. Vaccines being developed include inactivated whole-virus, live attenuated, subviral particle, and DNA vaccines.

Introduction

Enteroviruses are small, single-stranded, positive-sense RNA viruses from the enterovirus genus in the family Picornaviridae. They cause disorders with a wide range of clinical manifestations, including cutaneous, visceral, and neurological diseases. For many years polyomaviruses were the most important enteroviruses, since they led to large outbreaks of paralytic disease. A global campaign has, however, almost eradicated poliomyelitis from many regions worldwide. In its place, enterovirus 71 (EV71) causes major outbreaks of hand, foot, and mouth disease (HFMD), most frequently affecting children. This virus was first described in 1969, although an analysis shows that EV71 was circulating in the Netherlands as early as 1963. Although present in most countries, the largest outbreaks of disease have been seen in the Asia-Pacific region, for reasons that are incompletely understood. The neurological manifestations range from aseptic meningitis to acute flaccid paralysis and brainstem encephalitis, which is associated with systemic features, such as severe pulmonary oedema and shock, in many cases. The clinical features, investigations, and management of severe EV71 disease are discussed in a companion article in *The Lancet Neurology*. In this Review we consider the virology, clinical and molecular epidemiology, pathogenesis, and prospects for control.

Virology

Classification

As well as the enterovirus genus, the large Picornaviridae family includes Rhinovirus spp (eg, the common cold), Hepatovirus spp (eg, human hepatitis A virus), Parechovirus spp (eg, human parechovirus 1 and 2), and two important animal virus genera, Cardiovirus spp (eg, encephalomyocarditis virus) and Aphthovirus spp (foot and mouth disease virus). Human enteroviruses were traditionally separated into four classifications, according to their pathogenicity in human beings and experimental animals and their cytopathic effects in tissue culture; these subgroups were polioviruses (three serotypes), coxsackievirus A (23 serotypes), coxsackievirus B (six serotypes), and echoviruses (28 serotypes). However, because of the limitations of this system, serologically distinct human enteroviruses isolated since 1970 have been designated by serotype numbers, beginning with HEV68. The original classification of human enteroviruses has been substituted by a taxonomic scheme based on molecular and biological properties of the viruses. This revised classification recognises at least 90 subtypes and separates them into four species (table 1). Polioviruses have been designated as members of the human enterovirus C species because they are genetically closely related.

Physicochemical properties

The virus capsid comprises 60 identical subunits (protomers), each of which contains a copy of the four structural viral proteins (figure 1). The lack of a lipid envelope confers human enteroviruses stability in the host environment, including on exposure to human gastric acid, and they can survive at room temperature for several days. EV71 and other enteroviruses have also been detected in surface and ground water and in hot spas. Enteroviruses are resistant to organic solvents (eg, ether and chloroform), alcohol, and freezing, but can be inactivated by temperatures higher than 56°C, chlorination, formaldehyde, and ultraviolet irradiation. In one study EV71 was destroyed by virucidal disinfectants.

Life cycle and replication

Human beings are the only known natural hosts of human enteroviruses. Like most other enteroviruses the replication cycle of EV71 is similar to that of polioviruses. Viral entry into susceptible host cells is dependent on specific receptors. Seven receptors for different enteroviruses have been identified in human beings. The specific receptors include the poliovirus receptor (CD155), three integrins (α2β1, αvβ3, and αvβ6), decay-accelerating factor (CD55), the coxsackievirus-adenovirus receptor (CD46), and CD59.
receptor, and intracellular adhesion molecule 1. Some enteroviruses use more than one receptor to infect a host cell. Several receptors for EV71 have been identified, but a ubiquitously expressed cellular receptor, scavenger receptor B2, and a functional receptor, human P-selectin glycoprotein ligand-1, found on white blood cells, are specific for EV71. 27,28 Sialic-acid-linked glycan, which is expressed in abundance in the respiratory and gastrointestinal tracts, and dendritic-cell-specific intercellular adhesion-molecule-3-grabbing non-integrin (CD209), which is found exclusively in dendritic cells in lymphoid tissues, have also been identified.29–31

After an enterovirus binds with a specific receptor on the cell surface, a series of structural changes occur in the virus capsid (yet to be defined in EV71) and pores are formed in the cell membrane through which the virion RNA is released into the host cell cytoplasm. Being positive-sensed, the parent virus RNA acts directly as a messenger RNA and is translated into a large polypeptide that is promptly cleaved by the viral proteases into 11 mature structural and non-structural proteins. The replication of the virus genome by the error-prone RNA-dependent RNA polymerase 3Dpol takes place in a vesicle membrane structure (viral replication complex). The polymerase is estimated to misincorporate one or two bases in every genome copying event, which explains why the virus mutates and evolves rapidly. Within the VP1 gene $4\cdot2–4\cdot6\times10^{-3}$ nucleotide substitutions occur per site per year, which is similar to the number in poliovirus and greater than that of influenza viruses.32–34

While the machinery of the host cellular protein synthesis is shut down by viral protease 2A, viral protein synthesis remains unaffected. An infectious virus particle is formed after the packaging of a progeny viral RNA into a virus capsid in the cytoplasm of the infected cells. Mature infectious virus particles are released when an infected cell is lysed.

**Clinical epidemiology**

**Initial identification**

EV71 was isolated from the stool of a child aged 9 months with encephalitis, in California, USA, in 1969; although an earlier isolate has since been identified.1 Within 5 years small outbreaks of neurological infections, including encephalitis and aseptic meningitis, attributed to EV71 were reported in Australia, Japan, Sweden, and the USA.15–18

The dermotrophic properties of EV71 were first recognised when the virus caused epidemics of HFMD in Japan in 1973.18,39 In the 1970s, two large EV71 epidemics occurred in Europe. The first, in Bulgaria, was initially attributed to polioviruses because of the epidemiological, clinical, and pathological characteristics.40,41 EV71, confirmed by virus isolation or neutralisation test, was later identified as the causative agent in 347 (77%) of 451 children who presented with non-specific febrile illness or neurological disease; 44 children died. The second major epidemic was 3 years later in Hungary, with 1550 cases (826 aseptic meningitis, 724 encephalitis) and 47 deaths reported; unlike the Bulgarian epidemic, few patients had HFMD.42


**Table 1: Human enterovirus serotypes, by species**

<table>
<thead>
<tr>
<th>Serotype</th>
<th>A</th>
<th>B</th>
<th>C</th>
<th>D</th>
</tr>
</thead>
</table>


![Figure 1: Enterovirus 71 structure and genome structure of the virion](image-url)
Table 2: Enterovirus 71 genotypic subgroups reported to be circulating in the Asia-Pacific region between 1973 and 2008, by year9–14,45–53

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Singapore</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>B3</td>
<td>B4</td>
<td>B3</td>
<td>B3</td>
<td>B4</td>
<td>B4</td>
<td>B4</td>
<td>C1</td>
<td>B4</td>
<td>B4</td>
<td>B4</td>
<td>B5</td>
</tr>
<tr>
<td>Peninsular</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>B3*</td>
<td>B4*</td>
<td>C1</td>
<td>C1</td>
<td>C1*</td>
<td>C1</td>
<td>C1</td>
<td>C1</td>
<td>C1</td>
<td>C1</td>
<td>C4</td>
<td>B5</td>
</tr>
<tr>
<td>Malaysia</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>B3</td>
<td>B4</td>
<td>B3</td>
<td>B4</td>
<td>C1</td>
<td>C4</td>
<td>C1</td>
<td>B4</td>
<td>C1</td>
<td>B4</td>
<td>C1</td>
<td>C4</td>
</tr>
<tr>
<td>Sarawak, Malaysia</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
</tr>
<tr>
<td>Perth, Australia</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
</tr>
<tr>
<td>Japan</td>
<td>B1</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
</tr>
<tr>
<td>Taiwan</td>
<td>B1</td>
<td>B1</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>C2</td>
<td>B4</td>
<td>B4</td>
<td>B4*</td>
<td>B4</td>
<td>B4</td>
<td>C4</td>
<td>B5</td>
<td>C4</td>
<td>C4</td>
<td>C5</td>
<td>C5</td>
</tr>
<tr>
<td>Korea</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>C3*</td>
<td>None‡</td>
<td>None‡</td>
<td>None‡</td>
<td>None‡</td>
<td>C4</td>
<td>None‡</td>
<td>C4</td>
<td>None‡</td>
<td>C4</td>
<td>None‡</td>
</tr>
<tr>
<td>Brunei</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
</tr>
<tr>
<td>Vietnam</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
</tr>
<tr>
<td>Thailand</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
<td>..</td>
</tr>
<tr>
<td>China</td>
<td>..</td>
<td>..</td>
<td>C3</td>
<td>C4</td>
<td>..</td>
<td>..</td>
<td>C4</td>
<td>C4</td>
<td>C4</td>
<td>C4</td>
<td>C4</td>
<td>C4</td>
<td>C4</td>
<td>C4</td>
<td>C4</td>
<td>C4</td>
<td>C4</td>
<td>C4</td>
</tr>
</tbody>
</table>

*Genotypic subgroups caused large outbreaks. †Genotypic subgroup isolated in a small number of patients. ‡No enterovirus 71 detected, despite active surveillance.

Review

Asia-Pacific region

After the Australian and Japanese EV71 epidemics of the 1970s, further small epidemics and sporadic clusters occurred in Hong Kong in 1985,44 and in Australia in 1986.45 In 1997, a large outbreak of EV71 in Sarawak, Malaysia, heralded the start of a new series of outbreaks across the Asia-Pacific region (table 2).9–14,45–53

In Sarawak, 2618 HFMD cases and 34 deaths were recorded between May and July, 1997; around the same time EV71 caused four deaths in peninsular Malaysia and several cases of severe neurological disease in Japan.43,54 In 1998, the largest EV71 epidemic so far occurred in Taiwan:7 an estimated 1·5 million people were infected and 405 children were admitted to hospital for serious neurological complications, of whom 78 died. The latest large Asian-Pacific epidemic was in China in 2008, when around 490 000 infections and 126 deaths in children were reported; at the epicentre in Anhui Province, more than 6000 HFMD cases and 22 deaths in children were reported.65 In addition to these very large outbreaks, many areas, including Japan, Sarawak, Singapore, Taiwan, and Vietnam, have experienced cyclical epidemics that occur every 2–3 years (figure 2).3,5–7

Brainstem encephalitis, especially affecting the medulla, associated with cardiopulmonary dysfunction has become a notable feature in EV71 epidemics in Asia, and is the primary cause of death.4,9,12,17,58 This presentation is in contrast to that in the 1980s, when aseptic meningitis was the most frequent neurological involvement.45–57 Children typically present with a brief febrile illness and mild neurological signs, after which they develop signs of tachycardia, poor perfusion, and tachypnoea that rapidly develop into acute, intractable cardiac dysfunction and fulminant—in many cases fatal—pulmonary oedema or haemorrhage.58 Neurogenic pulmonary oedema is thought to be the main pathogenic process.59,60

Other regions

Outside the Asia-Pacific region, EV71 has continued to circulate at a low level in Africa, Europe, and the USA and causes sporadic cases or small outbreaks. During a 1-year prospective study in Canada in 1998, 20 children with EV71 were admitted to a tertiary hospital, mostly in the summer or autumn months; half had aseptic meningitis, and a third had respiratory symptoms, but no symptoms were severe and all improved rapidly.60 Two small community outbreaks of neurological EV71 disease, without HFMD, occurred in 2003 and 2005 in Denver, CO, USA, affecting 16 children aged 4 weeks to 9 years; one child died.61 A retrospective analysis of stool samples collected from children admitted to hospital with aseptic meningitis in Austria between 2001 and 2004 showed that EV71 was detected in 16 (9%) of 181.62 A similar study identified 32 sporadic cases of EV71 infection in the UK between 1998 and 2006, presenting primarily as neurological disease, HFMD, or both.63 In the Netherlands, 58 people were admitted to hospital with EV71-associated fever, gastrointestinal symptoms, and CNS infections in 2007, after 21 years of low endemicity.64 Widespread asymptomatic circulation of EV71 was also noted between October 2002 and October 2003 in Norway, where the virus was isolated from 19 (17%) of 113 well children.65 EV71 was among a range of enteroviruses detected by the screening of blood donations in Scotland over 22 months; the detection rate for any enterovirus was one per 4000 donations,66 although the importance of this finding remains uncertain. In Nairobi, Kenya, two small institutional outbreaks of EV71 infection were reported in an HIV orphanage in 1999 and 2000.67

Molecular epidemiology

Gene groups, evolution, and geographical distribution

Phylogenetic analysis suggests that EV71 emerged from the coxsackievirus type A 16, as recently as 1940.68 The
first complete phylogenetic analysis of EV71 based on the structural VP1 gene identified three independent lineages of EV71, designated A, B, and C; each group has at least 15% divergence from the others. Group A consists of one member, the prototype BrCr strain, which was first identified in California, USA, in 1970, and was not reported outside the USA until 2008, when isolates were reported from five of 22 children presenting with HFMD in Anhui province of central China. Sequencing of the complete VP1 gene showed very little divergence between isolates. The virus might, therefore, have been circulating undetected in central China, with very little evolutionary change for 40 years, although the source of the virus templates that were sequenced could...
have affected the results. Surveillance data from the same outbreak by the Chinese Center for Disease Control and Prevention do not seem to indicate any group A viruses. Group B viruses, which were initially separated into subgroups, B1 and B2, owing to 12% divergence at the nucleotide level, were the predominant circulating strains in the 1970s and 1980s. Group C viruses, which were initially separated into the C1 and C2 subgroups, were identified in the mid-1980s (figure 3). Several subgroups have been added to groups B and C in the past 12 years, according to findings in the Asia-Pacific region (figure 3, table 2). Viruses in subgroups B3 and B4 are thought to have both circulated in the region since 1997. Group B5, was first isolated in Japan and Sarawak in 2003, caused epidemics in Brunei, Sarawak, and Taiwan in 2006. Except for the major community outbreak in Sydney in 1986, subgroup C1 viruses have been isolated mainly from sporadic cases since the mid-1980s, which suggests low-level circulation worldwide. Subgroup C2 viruses caused the outbreak in 1998, and an outbreak in Perth, Australia, in 1999. Group C3 was isolated in Japan in 1994, and in Korea in 2000. Subgroup C4 has been the predominant circulating subtype in mainland China since 2000, and has been reported in Japan, Vietnam, and Taiwan. Subgroup C5 has been reported in southern Vietnam and Taiwan. A genetically distinct EV71 strain (R13223, Genbank accession number AY179600 to AY179602), with no genetic relationship to other EV71 strains, was isolated in India in 2001 from one child with acute flaccid paralysis.

Transmission and epidemic potential

Surveillance systems for EV71 established in several countries in the Asia-Pacific region, mainly to monitor transmission and spread, have provided information on virus evolution during outbreaks. In Sarawak, viral activity has increased every 3 years since 1997. This pattern is closely associated with increases in community incidence of HFMD. Regular cyclical epidemics have also been seen in Fukushima Prefecture, Japan. Such cyclical activity is assumed to relate to the availability of new birth cohorts of children who have not been exposed to the virus. Prediction of the epidemic potential of particular genotypic subgroups has proved difficult, although some differences in virulence, judged by size of associated epidemics, exist.

Shifts in subgroup dominance have been reported in Sarawak and Vietnam. In Japan and Taiwan subgroups of the B and C viruses have caused epidemics at different times (table 2). By contrast, in the Netherlands group B viruses were predominant before 1986, but since 1987 dominance has shifted to group C viruses; cross-neutralisation among the group B but not group C viruses is a possible explanation, although experimental data seem not to support this theory. Older subgroups of EV71 have been circulating and causing low levels of disease for many years, whereas some of those in newly described subgroups, such as B5, possess antigenicity distinct from other viruses and might, therefore, have the potential to
cause very large outbreaks. Although outbreaks have so far been confined to the Asia-Pacific region, increasing rates of travel mean that every region could be at risk.

Recombination
Recombination events occur frequently within enterovirus species, and recombination between EV71 viruses, and occasionally between EV71 and other enteroviruses, such as coxsackievirus types A16 and A8, has also been reported. Since recombination most often involves non-structural gene regions or untranslated regions, the use of PCR that amplifies the VP1 gene region is thought to be robust for diagnosis.

Pathogenesis
Viral determinants of virulence
The factors that determine whether EV71 infection will be asymptomatic or lead to HFMD or severe neurological disease are unknown. For polioviruses, the 5′ untranslated region and VP1 genes contain virulence determinants. Several studies have, therefore, examined the relevant nucleotide sequences or the whole genome to compare isolates from fatal and non-fatal cases, but most isolates have been identical or nearly identical. The frequency of CNS disease and other severe complications of EV71 infection has varied between Asian outbreaks, which suggests differences in virulence of subtypes. However, comparisons of outbreak data have been hampered by differences in study designs and viral diagnostic capabilities.

Perhaps the strongest data that determinants of strain virulence have key roles in the pathogenesis of severe neurological disease come from outbreaks in Perth, Australia, and Sarawak. In Perth, in 1999, subgroups B3 and C2 were both circulating. C2 viruses linked to the Taiwan epidemic of 1998 were almost exclusively isolated from children with severe neurological disease, and only one isolate came from a case of uncomplicated HFMD. By contrast, B3 viruses, which were similar to those from the Sarawak 1997 epidemic, were isolated mainly from children with uncomplicated HFMD, aseptic meningitis, or those with neurological complications, none of whom died. In two discrete epidemics in Sarawak in which either B4 or B5 viruses were predominant, a study of 277 children with EV71-associated HFMD showed that B4 viruses were less likely than B3 viruses to cause CNS infection or be part of a family cluster.

Dual infection
During the 1997 EV71 B3 virus outbreak in Sarawak, an adenovirus type 21 was isolated in the patients who died and in some with acute flaccid paralysis. The virus was detected at autopsy in sterile sites, such as cerebrospinal fluid and brain and heart tissue, in more patients than EV71. This finding led to the suggestion that death was related to dual infection, but subsequent detailed studies, including longitudinal studies from Sarawak, have found no evidence of adenovirus 21 infection in other HFMD or neurological cases. Dual infection with EV71 and other viruses, including dengue and Japanese encephalitis, has been reported. Furthermore, adenovirus 21 has not been isolated in Sarawak since 1997.

Host susceptibility
Various factors could affect pathogenesis, especially partial cross-protective immunity from previous outbreaks, which might partly explain why young age is a risk factor for severe disease. One genetic study in Taiwan reported that HLA-A33 is associated with increased susceptibility to EV71 infection, although the role of MHC remains unknown. The researchers noted that HLA-A33 is more frequent in Asian populations than in white populations, which might explain the high number of EV71 epidemics in Asia. They suggested also that HLA-A2, in a mechanism yet to be defined, could be linked to the risk of cardiopulmonary failure in patients with EV71. The CTLA4 gene is an important regulator of T-cell cytotoxicity, and it has a role in the regulation of an immune response. In a study of 78 children with EV71 infection in Taiwan, those with meningoencephalitis had a higher frequency of G/G genotype at position 49 of exon 1 in this gene, than those without meningoencephalitis and controls. However, a subsequent study found no such association.

Pathophysiology of severe disease
Virus entry and spread
EV71 is transmitted predominantly via the faeco-oral route, but can also spread through contact with virus-contaminated oral secretions, vesicular fluid, surfaces or fomites, and in respiratory droplets. As with other enteroviruses, initial viral replication is presumed to occur in the lymphoid tissues of the oropharyngeal cavity (tonsils) and small bowel (Peyer’s patches), with further multiplication in the regional lymph nodes (deep cervical and mesenteric nodes), giving rise to a mild viraemia. Most infections are controlled at this point and remain asymptomatic. Further dissemination of enteroviruses to the reticuloendothelial system (liver, spleen, bone marrow, and lymph nodes), heart, lung, pancreas, skin, mucous membranes, and CNS coincides with the onset of clinical features. For EV71, viral shedding from the throat can occur up to 2 weeks after an acute EV71 infection, and virus can be isolated from stool for up to 11 weeks. Epidemiological and experimental studies suggest that polioviruses can invade the CNS system through a disrupted blood–brain barrier or retrograde axonal spread along cranial or peripheral nerves. For EV71, studies in mice and assessment of the distribution of virus and inflammation in fatal human cases implicate the latter route.
Pathological findings

CNS inflammation predominantly affects grey matter of the spinal cord and the whole medulla oblongata, including the dorsal nucleus of the vagus, tractus solitarius, the nucleus, and reticular formation. The hypothalamus and subthalamic and dentate nuclei, and to a lesser degree motor cortex of the cerebrum, are also involved (figure 4). Inflammatory changes were absent in cerebellar cortex, thalamus, basal ganglia, peripheral nerve, and autonomic ganglia. Histopathological changes, characterised by perivascular cuffs, variable oedema, neuronophagia, and microglia nodules, are similar to those in encephalitis caused by other viruses. However, virus inclusion has not been observed, and viral antigens and RNA can be seen in only a few neuronal processes and phagocytic cells.

Severe pulmonary oedema and heart failure

Although fulminant pulmonary oedema is preceded by and closely associated with CNS involvement, its cause is unclear, especially whether neurogenic pulmonary oedema, cardiac dysfunction, increased vascular permeability, and cytokine storm contribute (figure 5). Neurogenic pulmonary oedema classically follows head injury. In these cases, raised intracranial pressure is thought to be important, but the pathogenesis is not completely understood. Experimental studies suggest that the hypothalamus, vasomotor centres of the medulla, and nuclei in the cervical spinal cord are important; lesions to various nuclei in these regions can increase activity along the sympathetic trunk, resulting in severe systemic and pulmonary hypertension and pulmonary oedema. Damage to brainstem nuclei in poliomyelitis is thought to lead to pulmonary oedema of neurogenic origin. Thus, when severe pulmonary oedema was first seen in EV71 encephalitis along with brainstem inflammatory changes, oedema was thought to be neurogenic. Post-mortem examination and MRI studies of children with EV71 brainstem encephalitis showed extensive inflammation of grey matter of the spinal cord and the whole medulla oblongata. The observations of hyperglycaemia and leucocytosis were also postulated to be due to increased sympathetic discharges.

Severe systemic and pulmonary hypertension is not always seen in children with EV71-associated pulmonary oedema. Some commentators have argued that cardiac dysfunction is a major contributor to the pulmonary oedema. Although no histological or virological evidence of viral myocarditis is seen in patients with EV71 infection, raised concentrations of cardiac-specific troponin I suggest a degree of cardiac damage. An echocardiographic study in 11 children with EV71 brainstem encephalitis showed that cardiac function was impaired, indicated by substantially lowered left-ventricular ejection fractions. Two children whose cardiac output was supported with a left-ventricular assist device survived, whereas all the others died. In a separate report the same researchers described very high concentrations of norepinephrine

Figure 4: Pathological findings in enterovirus 71 encephalitis

(A) Parenchymal inflammation (arrow) and perivascular cuffing in the medulla. Severely inflamed areas show (B) oedema (asterisk) and (C) neuronophagia (arrow). (D) More subtle inflammation can be seen in the motor cortex, with mild perivascular cuffing (arrow) and parenchymal inflammatory cells (circle). (E) Numerous CD68-positive macrophages/microglia (arrows). (F) A CD8-positive lymphocyte adjacent to a neuron (arrow). (G) Viral RNA in the anterior horn cells of the spinal cord (arrows). (H) Viral antigens in the neuronal body and process in the hypothalamus. (I) Adjacent section of the same neuron that was positive for viral RNA, and (J) adjacent section that was positive for antigen. Stains: haematoxylin and eosin (A–D), immunohistochemistry/peroxidase/DAB (E, F), and ISH/nitroblue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate (G). Original magnifications: ×4 (A), ×10 (B and D), ×40 (C and F), and ×20 (G). Modified from the Journal of Neuropathology and Experimental Neurology, with permission of Wolters Kluwer.
and epinephrine in three of the 17 children with left-ventricular dysfunction.\textsuperscript{101}

Although patients with EV71 infection do not have myocardial inflammation, histological examination of cardiac ventricular tissue biopsy samples from six fatal cases and one survivor revealed notable coagulative myocyteysis, myofibrillar degeneration, and cardiomyocyte apoptosis, which are the characteristic features of catecholamine-associated cardiotoxic effects.\textsuperscript{101,104} Thus, high catecholamine concentrations caused by brainstem encephalitis are purported to have a direct effect on cardiac function, as well as to cause pulmonary oedema via raised pulmonary pressures.

The other potential contributor to pulmonary oedema, increased vascular permeability, might arise secondary to the systemic inflammatory response. Several studies have examined cytokine and chemokine profiles in EV71 patients with brainstem encephalitis: concentrations of interleukins 1B, 6, 10, and 13, tumour necrosis factor α, and interferon γ are all significantly higher in patients with EV71 with pulmonary oedema than in those without. Several of these cytokines are mediators of increased

---

**Figure 5:** The postulated pathogenesis of enterovirus-71-associated acute pulmonary oedema

EV71 = enterovirus 71. CNS = central nervous system. SVR = systemic vascular resistance. SBP = systemic blood pressure. HR = heart rate. LV = left ventricular.
vascular permeability. The high concentrations of several chemokines in plasma, including 10 kDa-interferon-γ-induced protein, monocyte chemoattractant protein, monokine induced by interferon γ, and interleukin 8, have been reported in children with brainstem encephalitis and pulmonary oedema. Children with oedema also had depleted lymphocyte populations, especially CD4, CD8, and natural killer cells. Thrombocytosis, neutrophilia, and hyperglycaemia are all thought to reflect a systemic inflammatory response. Cytokines in the cerebrospinal fluid are less studied than those in blood, but in one study patients with encephalitis complicated by oedema had high concentrations of interleukin 1β, compared with those who had encephalitis alone.

The development of pulmonary oedema in patients with EV71 encephalitis seems to be strongly associated with dysregulation of systemic and CNS inflammatory responses. This relation has formed at least part of the basis for anti-inflammatory therapy with intravenous immunoglobulin, and the approach does seem to be effective.

The exact mechanism for pulmonary oedema in EV71 encephalitis is unclear. Neurogenic mechanisms secondary to brainstem inflammation seem to be important, but pathologically similar changes are seen in other encephalitides, such as Japanese encephalitis, without pulmonary oedema being such a prominent feature. Cardiac dysfunction and the effects of the systemic inflammatory response on the vascular endothelium may also make important contributions. In-vivo models, including those in mice and non-human primates, have replicated some of the features of severe EV71 disease, such as neuroinvasion with inflammatory changes, but none has yet been able to reproduce the severe systemic features, such as pulmonary oedema.

Prospects for control

Surveillance and social distancing

The only measures available for disease control are public health approaches. Since early intervention can lessen the spread of the virus, many countries in the Asia-Pacific region, including Japan, Malaysia, Singapore, Taiwan, Vietnam, and Vietnam, have implemented heightened surveillance for EV71. HFMD has now become a notifiable disease in many countries in the region. However, since other enteroviruses, such as coxsackievirus types A 8, A 10, and A 16, can cause HFMD, concurrent virological surveillance is necessary. This approach can also provide invaluable molecular epidemiological data that might help to track the spread of the virus across the region.

Outbreak control measures are primarily targeted at interrupting virus transmission person to person and through contact with contaminated surfaces, toys, or fomites. Health education, therefore, focuses on personal hygiene and good sanitation, including frequent hand washing, proper disposal of soiled nappies, and disinfection of soiled surfaces with chlorinated (bleach) disinfectants.

The transmission of enteroviruses, including EV71, is most efficient in crowded settings and, therefore, most countries in the region, including Malaysia, Singapore, Taiwan, Hong Kong, and China, have adopted social distancing measures, such as closures of childcare facilities and schools, and cancellation of public functions involving children. Little systematic research has been done to assess the effectiveness of such measures, but one study from Singapore seemed to show some benefit. However, the optimum timing for implementation—as soon as an HFMD outbreak is reported or after it is confirmed to be caused by EV71—is uncertain. In addition, the effectiveness of distancing measures, which have substantial socioeconomic implications, is uncertain. If EV71 is like other directly transmissible viruses, such controls will decrease the peak incidence of disease, but the outbreak could be prolonged and, therefore, the overall number of cases might not be lower. Data from clinical and epidemiological studies are needed to guide public health decisions.

Vaccine development

No vaccines against EV71 exist, but by analogy with poliomyelitis, vaccination probably offers the best option for disease control. One limitation in EV71 vaccine development is the lack of a good mouse model of human disease. Adult mice are resistant to infection. Although suckling mice are susceptible, by the time immunity develops after inoculation, the animals have matured and become resistant to infection. One way around this issue is to vaccinate female adult mice, allow them to become pregnant, and then measure titres of protective maternal antibodies transferred to offspring, as judged by protection against lethal infection. Several comprehensive reviews on the development of EV71 vaccine candidates have been published. Various types of vaccines are being investigated, including inactivated whole-virus, live attenuated, subviral particle, and DNA vaccines. All types are in early stages of development, with the most advanced undergoing preclinical trials in mice and non-human primates.

Candidate inactivated vaccines include those derived in Taiwan from the B4 viruses EV71-075 and EV71-0117, which are highly immunogenic, and from EV71-1207, which is a C2 virus and is less immunogenic. In one
study all these vaccines were more immunogenic in mice than recombinant VP1 protein or DNA vectored vaccines. Virus-like particles for EV71, which resemble the virus in appearance and capsid and protein structure, have been produced and purified as potential vaccines. After immunisation of BALB/c mice, the particles induced potent and long-lasting humoral immune responses, reflected by high total IgG and neutralisation titres. Splenocytes collected from the immunised mice exhibited substantial cell proliferation and stimulated production of interferon γ and interleukins 2 and 4, indicating the induction of T-helper-1 and T-helper-2 immune responses. Immunisation of female mice conferred protection (survival up to 89%) to neonatal mice against virus challenge with a dose 1000 times that normally required to kill 50% of animals.

A potential DNA vaccine has been developed by inserting the VP1 gene into the pVAX1 vector, and transforming the constructs into Escherichia coli cells, followed by expression in a mammalian cell line. Immunisation of mice with the DNA vaccine constructs resulted in the production of antibodies to VP1 IgG and neutralising antibody against EV71. Oral immunisation of female mice with an attenuated Salmonella enterica serovar Typhimurium expressing the VP1 gene, also proved protective in newborn offspring. Transgenic tomatoes expressing the VP1 protein have been developed. Incorporation of this protein in an oral vaccine led to the development of VP1-specific antibodies and evidence of cell-mediated immunity in BALB/c mice, and provided protection to offspring in neonatal challenge models.

Linear neutralising epitopes from the VP1 capsid protein were identified in mice by raised concentrations of antisera against overlapping peptides from this protein, two of which elicited neutralising antibody responses. One of these peptides, SP70, was especially potent, and comparison with sequences from other strains showed it was conserved among the different genotypic subgroups of EV71, which suggests it is a promising vaccine candidate.

A live attenuated strain of EV71, EV71(S1-3), was derived from the genotype A prototype strain BrCr by genetic manipulation, on the basis of temperature-sensitive determinants of poliovirus type 1 vaccine strain, some of which are located in the 5’ and 3’ untranslated regions and the 3Dpol gene. Intravenous inoculation of cynomolgus monkeys led to the production of antibodies with cross-reactivity against a broad spectrum of EV71 genotypes that survived challenge with intravenous virulent EV71 (BrCr-TR strain), which is lethal to non-immunised monkeys. However, the vaccine strain itself caused mild neurological symptoms (tremor) and entered the spinal cord, which indicated that further work on attenuation is needed.

Among the various vaccine candidates, inactivated whole virus vaccines are in some ways the most ready to develop further, because the principles of vaccines based on inactive whole virus are well established. However, experience with vaccination against Japanese encephalitis, another major neurological infection in Asia, has shown that issues over cost and availability can limit the widespread uptake of vaccines in poor Asian countries. If a vaccine is to be used across the whole of Asia, it needs to be cheap, easily produced, and readily available.

Conclusions
The increased size and frequency of EV71 outbreaks in the Asia-Pacific region over the past 12 years has been an important public health issue. Molecular epidemiological studies suggest that some viral genotypic subgroups seem

Figure 6: Comparison of data from sentinel surveillance centres on effects of public health interventions on hand, foot, and mouth disease in Sarawak, Malaysia, in 2003 and 2006. The public health response was limited in 2003, but more-rigorous social distancing measures were encouraged in 2006.
to have massive potential for explosive epidemics, whereas others have more-indolent, low-level circulation. However, the biological determinants of these differences are poorly understood. The reasons for epidemiological differences between EV71 in the Asia-Pacific region and that in Europe and the USA are also unclear, as are the virological and host determinants of the wide-ranging clinical phenotypes in infected individuals. Although some animal models of neurological disease caused by EV71 are reasonable, a good model of cardiorespiratory dysfunction is urgently required to help understand pathogenesis better.

The public health measures currently used during EV71 epidemics are empirical and generic, have high socioeconomic impact and are not clearly effective. Further research is needed on virus transmission. The identification of several EV71 receptors might help in drug discovery. Several vaccine candidates are under development, but the logistical issues of how to reach their target paediatric populations remain important.

Contributors
TS and MHO conceived and designed this Review. TS, PL, DP, MJC, PM, and MHO drafted the paper and critically revised it.

Acknowledgments
MHO is a Wellcome Trust Training Fellow. TS is an MRC Senior Clinical Fellow. We thank the Liverpool NIHR Biomedical Research Centre in Microbial Diseases for support.

Conflicts of Interest
MJC joined Sentinelx Therapeutics, a Malaysian biotechnology start-up company involved in the development of a vaccine against enterovirus 71, as Chief Scientific Officer in September, 2010, but was not employed by the company during the design or preparation of this Review. TS, MJC, and MHO have acted as informal advisers to WHO on hand, foot, and mouth disease and enterovirus 71 infection. PL, DP, and PM declare that they have no conflicts of interest.

References